Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

Capricor Therapeutics Securities Class Action

Capricor Therapeutics · Capricor securities and Deramiocel for Duchenne muscular dystrophy-associated cardiomyopathy · New Filing

About this case

A securities class action has been filed on behalf of investors who acquired Capricor Therapeutics common stock between December 17, 2025, and July 26, 2026. The complaint alleges that Capricor made materially false or misleading statements and failed to disclose information about changes to the statistical analysis plan for Deramiocel and related risks to regulatory approval; the matter is at the filing and lead-plaintiff appointment stage.

Case overview

Defendant company
Capricor Therapeutics
Product or service
Capricor securities and Deramiocel for Duchenne muscular dystrophy-associated cardiomyopathy
Case name
Nkamga v. Capricor Therapeutics, Inc., et al.
Court case number
3:26-cv-04385-GPC-AHG
Case status
New Filing
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Class Action Information and Representation Inquiry
Lead Plaintiff Appointment

Participation information

Class Action Information and Representation Inquiry

Investors who purchased Capricor securities during the stated class period may contact the law firm regarding the lawsuit.

Use the law firm's case page to obtain information about joining or pursuing the class action.

Type
Law Firm Signup
Status
Open
Reported proof requirement
Unclear
Contact law firm Contact law firm

Lead Plaintiff Appointment

Investors who acquired eligible Capricor securities during the stated class period may seek appointment as lead plaintiff, subject to the court’s requirements.

Submit a lead-plaintiff application by September 28, 2026. Investors who do not seek appointment may remain absent class members.

Type
Lead Plaintiff
Status
Open
Reported proof requirement
Unclear

Capricor shareholder legal inquiry

The notice invites individuals who purchased Capricor shares between December 17, 2025 and July 26, 2026 and experienced an investment loss to discuss their legal rights.

Contact Corey D. Holzer, Esq. by email at cholzer@holzerlaw.com or by telephone at (888) 508-6832. The article also provides the law firm's website address for additional information.

Type
Law Firm Signup

Lead Plaintiff Application

Investors who purchased or otherwise acquired Capricor Therapeutics securities during the stated class period may seek appointment as lead plaintiff.

Investors must move the court to serve as lead plaintiff within 60 days of the notice.

Type
Lead Plaintiff
Status
Open
Source version Business Wire source version Source version

Sources